SCHEMBL8566607

SCHEMBL8566607

Cc1ncc(CN)o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2629342 0.78
SCHEMBL873971 0.76
SCHEMBL5540227 0.76
SCHEMBL22792609 0.76
SCHEMBL15229474 0.76
SCHEMBL5833261 0.76
SCHEMBL5535219 0.74
SCHEMBL10863000 0.74 CHRM2 (0.39)
SCHEMBL21578172 0.73
SCHEMBL13819887 0.73 FEN1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
US-20250281483-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF Astellas Engineered Small Molecules US, Incorporated 2025-09-11 US disclosed
EP-4511112-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF Astellas Engineered Small Molecules US, Incorporated (US) 2025-02-26 EP disclosed
CN-117964547-A Urea compound and application thereof as Sigma2 and 5HT2A dual-target inhibitor 瀚远医药有限公司 2024-05-03 CN disclosed
WO-2024067304-A1 COMPOUND WITH INHIBITORY ACTIVITY AGAINST SIGMA2 AND 5HT2A AND USE 瀚远医药有限公司 2024-04-04 WO disclosed
US-11851425-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines H. LUNDBECK A/S (DK) 2023-12-26 US disclosed
WO-2023205415-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF MITOBRIDGE INC. (US) 2023-10-26 WO disclosed
WO-2023205415-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF MITOBRIDGE INC. (US) 2023-10-26 WO disclosed
EP-4013500-B1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS NOVARTIS AG (CH) 2023-10-25 EP disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 EP disclosed
WO-2018007249-A1 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS H. LUNDBECK A/S (DK) 2018-01-11 WO disclosed
US-20180000786-A1 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors H. LUNDBECK A/S (DK) 2018-01-04 US disclosed
US-20150299120-A1 Spirohydantoin compounds and their use as selective androgen receptor modulators AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-10-22 US disclosed
US-20150299120-A1 Spirohydantoin compounds and their use as selective androgen receptor modulators AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-10-22 US disclosed
US-20150299120-A1 Spirohydantoin compounds and their use as selective androgen receptor modulators AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-10-22 US disclosed
EP-2819999-A1 SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS Novartis AG (CH) 2015-01-07 EP disclosed
WO-2013128421-A1 SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS NOVARTIS AG (CH) 2013-09-06 WO disclosed
EP-0539421-B1 NOVEL OXAZOLYL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 1998-09-23 EP disclosed
US-5278165-A Oxazolyl imidazol[4,5-b]pyridin and pyrimidine compounds JANSSEN PHARMACEUTICA N.V. (BE) 1994-01-11 US disclosed
US-5217980-A Antiallergens JANSSEN PHARMACEUTICA N.V. (BE) 1993-06-08 US disclosed